Cardiovascular Diabetology (Sep 2024)

Metabolically “extremely unhealthy” obese and non-obese people with diabetes and the risk of cardiovascular adverse events: the Silesia Diabetes - Heart Project

  • Oliwia Janota,
  • Marta Mantovani,
  • Hanna Kwiendacz,
  • Krzysztof Irlik,
  • Tommaso Bucci,
  • Steven H. M. Lam,
  • Bi Huang,
  • Uazman Alam,
  • Giuseppe Boriani,
  • Mirela Hendel,
  • Julia Piaśnik,
  • Anna Olejarz,
  • Aleksandra Włosowicz,
  • Patrycja Pabis,
  • Wiktoria Wójcik,
  • Janusz Gumprecht,
  • Gregory Y. H. Lip,
  • Katarzyna Nabrdalik

DOI
https://doi.org/10.1186/s12933-024-02420-x
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background There is a growing burden of non-obese people with diabetes mellitus (DM). However, their cardiovascular risk (CV), especially in the presence of cardiovascular-kidney-metabolic (CKM) comorbidities is poorly characterised. The aim of this study was to analyse the risk of major CV adverse events in people with DM according to the presence of obesity and comorbidities (hypertension, chronic kidney disease, and dyslipidaemia). Methods We analysed persons who were enrolled in the prospective Silesia Diabetes Heart Project (NCT05626413). Individuals were divided into 6 categories according to the presence of different clinical risk factors (obesity and CKM comorbidities): (i) Group 1: non-obese with 0 CKM comorbidities; (ii) Group 2: non-obese with 1–2 CKM comorbidities; (iii) Group 3: non-obese with 3 CKM comorbidities (non-obese “extremely unhealthy”); (iv) Group 4: obese with 0 CKM comorbidities; (v) Group 5: obese with 1–2 CKM comorbidities; and (vi) Group 6: obese with 3 CKM comorbidities (obese “extremely unhealthy”). The primary outcome was a composite of CV death, myocardial infarction (MI), new onset of heart failure (HF), and ischemic stroke. Results 2105 people with DM were included [median age 60 (IQR 45–70), 48.8% females]. Both Group 1 and Group 6 were associated with a higher risk of events of the primary composite outcome (aHR 4.50, 95% CI 1.20-16.88; and aHR 3.78, 95% CI 1.06–13.47, respectively). On interaction analysis, in “extremely unhealthy” persons the impact of CKM comorbidities in determining the risk of adverse events was consistent in obese and non-obese ones (Pint=0.824), but more pronounced in individuals aged < 65 years compared to older adults (Pint= 0.028). Conclusion Both non-obese and obese people with DM and 3 associated CKM comorbidities represent an “extremely unhealthy” phenotype which are at the highest risk of CV adverse events. These results highlight the importance of risk stratification of people with DM for risk factor management utilising an interdisciplinary approach.

Keywords